حدد سهمًا أو عملة مشفرة في شريط البحث للحصول على ملخص
Strides Pharma Science Limited
STARStrides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India. Address: Strides House, Bengaluru, India, 560076
Analytics
سعر الهدف في وول ستريت
158 475.75 INRنسبة السعر إلى الأرباح
80العائد الربحي
0.18 %السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
السنة الحالية
العام الماضي
الربع الحالي
الربع الأخير
الشخصيات الرئيسية STAR
تحليلات الأرباح STAR
نمو الأرباح على مدى 5 سنوات
-25 %النمو المستمر
1 سنةمعدل الدفع 5 سنوات في المتوسط
23 %تاريخ الأرباح STAR
تقييم الأسهم STAR
المالية STAR
نتائج | 2019 | ديناميات |